Table 3.
Average cost-effectiveness ratios
| Compliance rate (%) | Target goal attainment (LDL-C level <100 mg/dL, %) | Probability (%) | Total cost (KRW) | ACER (KRW) | |
|---|---|---|---|---|---|
| Single-pill (ATR/AML) | Adherence (71.8) | Attainment (67.0) | 56.3 | 232.126 | 4.123 |
| Not attainment (33.0) | |||||
| Non-adherence (28.2) | Attainment (29.0) | ||||
| Not attainment (71.0) | |||||
| Double-pill (ATR+AML) | Adherence (52.9) | Attainment (67.0) | 49.1 | 297.653 | 6.062 |
| Not attainment (33.0) | |||||
| Non-adherence (47.1) | Attainment (29.0) | ||||
| Not attainment (71.0) |
Modified from Patel BV, et al. Vasc Health Risk Manag 2008:4:673-681 [11].
LDL-C, low density lipoprotein cholesterol; KRW, Korean won; ATR, atorvastatin; AML, amlodipine.